SOMATOSTATIN (SRIF) AND GLUCAGON IN DIABETES - FAILURE OF GLUCAGON SUPPRESSION TO IMPROVE IV GLUCOSE-TOLERANCE AND EVIDENCE OF AN EFFECT OF SRIF ON GLUCOSE-ABSORPTION

被引：0
|
作者：
WAHREN, J
FELIG, P
机构：
[1] KAROLINSKA INST,SERAFIMER HOSP,S-10401 STOCKHOLM 60,SWEDEN
[2] YALE UNIV,SCH MED,NEW HAVEN,CT 06510
来源：
ACTA PHYSIOLOGICA SCANDINAVICA | 1976年
关键词：
D O I：
暂无
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页码：148 / 148
页数：1
相关论文
共 49 条
  • [41] The Potentiating Effect of GLP-1 on Glucose-induced Glucagon Suppression in Healthy Individuals and in Patients with Type 1 and 2 Diabetes
    Bagger, Jonatan I.
    Lund, Asger
    Grondahl, Magnus
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES, 2016, 65 : A487 - A487
  • [42] Diabetes-Associated Variation in TCF7L2 Is Associated with a Longitudinal Decline in Glucose Tolerance Accompanied by Impaired Suppression of Postprandial Glucagon Secretion
    Zeini, Maya
    Muthusamy, Kalpana
    Egan, Aoife M.
    Laurenti, Marcello C.
    Cobelli, Claudio
    Man, Chiara Dalla
    Vella, Adrian
    DIABETES, 2023, 72
  • [43] EFFECT OF SOMATOSTATIN (S) ON BLOOD-GLUCOSE (BG), HUMAN GROWTH-HORMONE (HGH), IMMUNOREACTIVE INSULIN (IRI) AND GLUCAGON (IRG) RESPONSE TO IV GLUCOSE AND ARGININE IN HEALTHY SUBJECTS AND MATURITY ONSET DIABETICS
    BRATUSCHMARRAIN, P
    WALDHAUSL, W
    HAYDL, H
    DUDCZAK, R
    DIABETOLOGIA, 1976, 12 (04) : 382 - 382
  • [44] SELECTIVE FAILURE OF PROLONGED INFUSION OF INSULIN TO NORMALIZE GLUCAGON RESPONSES TO GLUCOSE IN HUMAN DIABETES-MELLITUS - EVIDENCE FOR A DEFECTIVE ALPHA-CELL GLUCORECEPTOR
    GERICH, JE
    LORENZI, M
    TSALIKIAN, E
    BOHANON, N
    SCHNEIDER, V
    KARAM, J
    FORSHAM, PH
    LEWIS, SB
    CLINICAL RESEARCH, 1976, 24 (03): : A361 - A361
  • [45] Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
    F. K. Knop
    T. Vilsbøll
    S. Madsbad
    J. J. Holst
    T. Krarup
    Diabetologia, 2007, 50 : 797 - 805
  • [46] Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
    Knop, F. K.
    Vilsboll, T.
    Madsbad, S.
    Holst, J. J.
    Krarup, T.
    DIABETOLOGIA, 2007, 50 (04) : 797 - 805
  • [47] In Vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1)
    Bala, Margarita
    Martin, Josefine
    Kopp, Andrea
    Hanses, Frank
    Buechler, Christa
    Schaeffler, Andreas
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (08): : 2493 - 2501
  • [48] The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
    Foghsgaard, Signe
    Vedtofte, Louise
    Mathiesen, Elisabeth R.
    Svare, Jens A.
    Gluud, Lise L.
    Holst, Jens J.
    Damm, Peter
    Knop, Filip K.
    Vilsboll, Tina
    BMJ OPEN, 2013, 3 (10):
  • [49] Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims
    Wang, Xuan
    Plantinga, Anna M.
    Xiong, Xin
    Cromer, Sara J.
    Bonzel, Clara-Lea
    Panickan, Vidul
    Duan, Rui
    Hou, Jue
    Cai, Tianxi
    JMIR DIABETES, 2024, 9
12345